Navigation Links
Siemens Receives FDA Approval for the VERSANT 440 Molecular System
Date:2/18/2008

Siemens Offers Next Generation Molecular Viral Load Testing to the U.S.

Market

DEERFIELD, Ill., Feb. 18 /PRNewswire/ -- Siemens Healthcare (http://www.siemens.com/diagnostics) announced today that its VERSANT(TM) 440 Molecular System has been approved for marketing by the U.S. Food and Drug Administration (FDA) for use with the VERSANT HCV RNA 3.0 assay for management of HCV-infected patients undergoing antiviral therapy. The VERSANT 440 Molecular System represents the next generation in automated viral load testing, providing laboratories with greater throughput and less hands-on time, maximizing productivity to meet the evolving needs of the clinical laboratory.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080218/NYM009 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

"We are pleased to offer clinical laboratories leading-edge solutions in molecular diagnostics that support cost-effective and timely screening and treatment of infectious disease," said Jim Reid-Anderson, Chief Executive Officer, Siemens Healthcare Diagnostics Division. "The VERSANT 440 Molecular system provides clinical laboratories and physicians an outstanding tool that enables quantitative monitoring of Hepatitis C and the delivery of personalized treatment that addresses the unique needs of every patient."

The VERSANT 440 Molecular System is a branched DNA (bDNA) system designed for flexible walk-away automation. Its single room technology and consolidated footprint allow the system the flexibility to fit anywhere in the clinical laboratory. The VERSANT 440 System streamlines workflow by integrating bar code data entry, automated reagent processing, signal amplification detection, and a Laboratory Information System interface for downloading patient work lists and results.

"At Siemens, we are intently focused on the development of advanced systems and solutions that will help clinical laboratories enhance their diagnostic capabilities and the efficiency of their operations," said David Okrongly, senior vice president, Molecular Diagnostics, Siemens Healthcare Diagnostics. "We are excited by the VERSANT 440 System's ability to advance molecular testing capability and productivity for our customers through optimized automation, system flexibility, and assay performance excellence."

The VERSANT 440 Molecular System uses bDNA technology that simplifies testing by eliminating nucleic acid extraction and reducing the risk of cross-contamination. With a high level of reproducibility, VERSANT HCV 3.0 Assay allows viral load changes to be distinguished accurately, enhancing hepatitis C viral load management. The HCV RNA 3.0 Assay run on the VERSANT 440 demonstrates excellent precision across the entire reporting range and equivalent detection of all HCV RNA genotypes. CE Marked in September of 2006, the VERSANT 440 has been successfully launched throughout Europe, Africa, and parts of Asia and the Americas.

About Siemens Healthcare Diagnostics

Siemens Healthcare Diagnostics Division is the leading clinical diagnostics provider in the world. The company offers health care professionals the broadest range of diagnostic products and services that are used for diagnosing medical conditions, monitoring patient therapy and providing quality health care. Siemens' comprehensive portfolio of solutions and highly responsive service are designed to improve clinical outcomes, streamline workflow and enhance the operational efficiency of clinical laboratories around the world. Visit http://www.siemens.com/diagnostics.

About Siemens Healthcare

Siemens Healthcare is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare will be the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care -- from prevention and early detection, to diagnosis, therapy and care. The company employs more than 49,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of euro 1.32 billion. Further information can be found by visiting http://www.siemens.com/healthcare.


'/>"/>
SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Siemens Healthcare Kicks Off New Era of Expanded Access to High-Field MRI with First Install of Affordable MAGNETOM ESSENZA
2. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
3. VIDEO from Medialink and Siemens: Doctors Trade in their Stethoscopes for Microphones
4. ...And the Grand Prize Goes to... Lockport Memorial Hospital, Winner of Siemens National Win an MRI Contest
5. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
6. Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions
7. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
8. The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology
9. Siemens Financial Services, Inc. Announces Completion of Credit Facility With Merit Mountainside, LLC
10. Siemens Releases New Version of INVISION to Aid Customers in Streamlining Clinical Workflow and Improving Quality of Care
11. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About ... most certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently ... , The new mold law in the district of Columbia is a ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Halfway through its ... has provided preventative dental services to more than 15,900 children 5 years old and ... LA pledged $38 million over a span of five years to Western University of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Two years ago, Arizona State ... watched live by 1 million viewers and won numerous honors, including the region’s ... at the Walter Cronkite School of Journalism and Mass Communication are following up ...
(Date:12/2/2016)... ... December 02, 2016 , ... For over twenty-four years, Doctors on Liens has ... injury victims find high quality medical care. When the company started in 1997, the ... forward to present day and the now ten-page directory features a vast array of ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... ALEXANDRIA, Va. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... year by the Academy of Managed Care Pharmacy ... care organizations can better address the opioid addiction ... Medication Assisted Therapies (MAT). ATAG,s newly ... in Improving Access to Naloxone," addresses many issues ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... -- Orthopedic Implants (Including Spinal Implants, Reconstructive Joint ... a Significant Market Share Owing to a Large Global Baby ... ... According to a new report by Persistence Market Research ... Product Type Segment Projected to Witness a Significantly High CAGR ...
Breaking Medicine Technology: